IRX-2 is not given alone. Instead, it is given as part of regimens containing additional pharmacologic agents that can support the promotion of an anticancer immune response. One regimen (the IRX-2 Neoadjuvant Regimen) is given before curative surgery, another (the IRX-2 Booster Regimen) is given after surgery.
The components of each regimen are the same, except for differences in administration timing and location, as well as treatment duration.
Following neoadjuvant treatment and curative surgery, patients receive 4 additional treatments with an abbreviated IRX-2 Booster Regimen given 3, 6, 9, and 12 months after surgical resection. (The “3-month” booster regimen may be initiated before or after completion of radiation or chemoradiation adjuvant therapy.)
The IRX-2 Booster Regimen is administered over 10 days, during which it is injected bilaterally into the deltoid region for 5 days. The booster regimen comprises:
During the IRX-2 Booster Regimen, agents are administered at the same daily doses as in the IRX-2 Neoadjuvant Regimen.